Latest Capital Raising News

Freehill Mining Ltd’s December quarter cash flow report reveals a $114,000 net cash outflow from operations but highlights a solid liquidity position with $301,000 in unused financing facilities.

C29 Metals closes December quarter with $2.56 million cash and key drilling approvals for its Ulytau uranium project, but faces a significant hurdle after Ministerial refusal to transfer ownership of its Kazakhstan tenement.

Silver Metal Group has completed the sale of its Texas Project, shedding operational costs and debt, while focusing on exploration planning amid tight cash reserves and ongoing capital raising efforts.

Rapid Lithium Ltd has completed its acquisition of Midwest Lithium and initiated a $2 million entitlement offer, marking a strategic pivot towards US and Canadian exploration projects.

Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.

Cauldron Energy’s December quarter report highlights a breakthrough uranium discovery at Manyingee South within the Yanrey Project, alongside a successful $4 million capital raise to fund ongoing exploration.

Tolu Minerals reports significant progress in recommencing production and expanding resources at its Tolukuma mine, underpinned by strategic hires and advanced geophysical surveys.

Audio Pixels Holdings Limited reports significant technical progress in its Digital Sound Reconstruction technology and secures additional funding through convertible notes, while continuing to navigate ASX suspension challenges.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Structural Monitoring Systems plc has raised $8.7 million and implemented a major cost restructuring, positioning itself for profitable growth with strong sales momentum in its avionics and sensor technology segments.